Organization | OncoPep, Inc.

OncoPep, Inc. Report issue

For profit Phase 1 Phase 2

Founded: North Andover MA United States (2010)

Organization Overview

First Clinical Trial

2012

NCT01718899

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

OncoPep, Inc.

Active Ingredients

Drugs in Phase 2 Trials (8)

autologous lymphocytes (1 trial)

hemopoietic stem cell (1 trial)

inactivated influenza vaccine (1 trial)

melphalan (alkeran) (1 trial)

peripheral blood hematopoietic cell (1 trial)

pvx-410 (1 trial)

revlimid (4 trials)

tetanus toxoid (1 trial)

Drugs in Phase 1 Trials (3)

durvalumab (imfinzi) (2 trials)

lenalidomide (revlimid) (1 trial)

poly-iclc (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Smoldering Multiple Myeloma (Phase 1)

Triple Negative Breast Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 5
# of Trial APIs: 11